OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC. METHODS Thirty patients with cutan...OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC. METHODS Thirty patients with cutaneous B-cell lymphoma （CBCL） were treated by cutaneous irradiation based on the number and location of the lesions and the stage of their tumor. Treatment was conducted using a Satume Clinac. RESULTS A complete response （CR） from the treatment for our series was 86%. The length of complete remission ranged from 4 to 301 months. Three patients （11%） developed a partial response （PR）. One patient was progressive. Disease-free survival（DFS） at 10 years was 87%. Three patiens died [One PCMZL two PCLBCL leg type （29%）]. Radiotherapy was generally well tolerated. CONCLUSION According to the WHO/EORTC classification, the survivor results were good for PCMZL and PCFCL. The PCLBCL leg type had a poor prognosis. Localized field irradiation is an effective treatment for some localized forms of primary cutaneous B-cell lymphoma, and this mode of therapy can produce prolonged remissions.The patients with wide-spread skin involvement are usually candidates for extended field irradiation and/or chemotherapy. For advanced stages of cutaneous B-cell lymphoma, where chemotherapy is the treatment of choice, a degree of palliation can be achieved using local field irradation.展开更多
目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释...目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释片联合布洛芬缓释片,重度癌痛患者使用盐酸吗啡缓释片联合布洛芬缓释片联合醋酸地塞米松片处理,治疗组在对照组基础上加用复方苦参注射液,21 d为1个疗程。观察比较两组治疗后的疼痛有效缓解率以及疼痛程度数字评估量表(numerical rating scale,NRS)、EORTC QLQ—C30(EuroPean organization for Research and Treatment)量表评分、匹兹堡睡眠质量指数与安全性。结果经治疗,治疗组有效缓解率升高(P<0.05);治疗组的NRS评分明显升高(P<0.01);EORTC QLQ—C30量表评分部分升高(P<0.05);匹兹堡睡眠质量指数明显升高(P<0.01);两组在治疗期间均出现不良反应,但治疗组不良事件发生率在恶心呕吐与便秘两方面更低(P<0.05);结果差异均有统计学意义(P<0.05)。结论在WHO三阶梯止痛原则基础上,加用复方苦参注射液可以明显提高止痛效果,明显改善生活质量,提高患者睡眠质量,同时也可降低不良事件发生情况,因此值得在临床推广应用。展开更多
Background The World Health Organization and European Organization for Research and Treatment of Cancer （WHOEORTC） classification in 2005 promoted the comparisons of primary cutaneous lymphoma （PCL） subtypes betwe...Background The World Health Organization and European Organization for Research and Treatment of Cancer （WHOEORTC） classification in 2005 promoted the comparisons of primary cutaneous lymphoma （PCL） subtypes between different countries.The relative frequency of PCL varied according to geography.The study aimed to analyze the relative frequency and survival of PCLs in China and to compare the data with the published results from other countries.Methods We analyzed 98 patients with PCLs over a 6-year period and reclassified them according to the most recent WHO-EORTC classification （2005）.Disease-specific survival rate and curves according to specific subtypes such as mycosis fungoides,lymphomatoid papulosis,and primary cutaneous peripheral T-cell lymphoma,unspecified was also calculated.Results The relative rate of PCL in China was distinct from those in Western countries.Our study showed a higher frequency of cutaneous T-and NK-cell lymphomas （CTCLs） （94%）,and a lower frequency of cutaneous B-cell lymphomas （CBCLs） （6%）.The 5-year survival rate of the total PCLs was 82%.There was no significant difference in the 5-year survival rate （P 〉0.05 by Log-rank test） between CTCL （80%） and CBCL （100%）.Conclusions The higher percentage of CTCL in China may provide a clue to further study the etiological factors of PCLs.Racial variations in factors such as HLA determinants may play a role in the development of CTCL.展开更多
文摘OBJECTIVE To report results of radiation therapy treatment of 30 B-cell lymphoma patients with an initial cutaneous presentation according to the new classification by the WHO/EORTC. METHODS Thirty patients with cutaneous B-cell lymphoma （CBCL） were treated by cutaneous irradiation based on the number and location of the lesions and the stage of their tumor. Treatment was conducted using a Satume Clinac. RESULTS A complete response （CR） from the treatment for our series was 86%. The length of complete remission ranged from 4 to 301 months. Three patients （11%） developed a partial response （PR）. One patient was progressive. Disease-free survival（DFS） at 10 years was 87%. Three patiens died [One PCMZL two PCLBCL leg type （29%）]. Radiotherapy was generally well tolerated. CONCLUSION According to the WHO/EORTC classification, the survivor results were good for PCMZL and PCFCL. The PCLBCL leg type had a poor prognosis. Localized field irradiation is an effective treatment for some localized forms of primary cutaneous B-cell lymphoma, and this mode of therapy can produce prolonged remissions.The patients with wide-spread skin involvement are usually candidates for extended field irradiation and/or chemotherapy. For advanced stages of cutaneous B-cell lymphoma, where chemotherapy is the treatment of choice, a degree of palliation can be achieved using local field irradation.
文摘目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释片联合布洛芬缓释片,重度癌痛患者使用盐酸吗啡缓释片联合布洛芬缓释片联合醋酸地塞米松片处理,治疗组在对照组基础上加用复方苦参注射液,21 d为1个疗程。观察比较两组治疗后的疼痛有效缓解率以及疼痛程度数字评估量表(numerical rating scale,NRS)、EORTC QLQ—C30(EuroPean organization for Research and Treatment)量表评分、匹兹堡睡眠质量指数与安全性。结果经治疗,治疗组有效缓解率升高(P<0.05);治疗组的NRS评分明显升高(P<0.01);EORTC QLQ—C30量表评分部分升高(P<0.05);匹兹堡睡眠质量指数明显升高(P<0.01);两组在治疗期间均出现不良反应,但治疗组不良事件发生率在恶心呕吐与便秘两方面更低(P<0.05);结果差异均有统计学意义(P<0.05)。结论在WHO三阶梯止痛原则基础上,加用复方苦参注射液可以明显提高止痛效果,明显改善生活质量,提高患者睡眠质量,同时也可降低不良事件发生情况,因此值得在临床推广应用。
文摘Background The World Health Organization and European Organization for Research and Treatment of Cancer （WHOEORTC） classification in 2005 promoted the comparisons of primary cutaneous lymphoma （PCL） subtypes between different countries.The relative frequency of PCL varied according to geography.The study aimed to analyze the relative frequency and survival of PCLs in China and to compare the data with the published results from other countries.Methods We analyzed 98 patients with PCLs over a 6-year period and reclassified them according to the most recent WHO-EORTC classification （2005）.Disease-specific survival rate and curves according to specific subtypes such as mycosis fungoides,lymphomatoid papulosis,and primary cutaneous peripheral T-cell lymphoma,unspecified was also calculated.Results The relative rate of PCL in China was distinct from those in Western countries.Our study showed a higher frequency of cutaneous T-and NK-cell lymphomas （CTCLs） （94%）,and a lower frequency of cutaneous B-cell lymphomas （CBCLs） （6%）.The 5-year survival rate of the total PCLs was 82%.There was no significant difference in the 5-year survival rate （P 〉0.05 by Log-rank test） between CTCL （80%） and CBCL （100%）.Conclusions The higher percentage of CTCL in China may provide a clue to further study the etiological factors of PCLs.Racial variations in factors such as HLA determinants may play a role in the development of CTCL.
